Teva Pharmaceutical Industries Ltd. ADR (TEVA) News
Filter TEVA News Items
TEVA News Results
|Loading, please wait...|
TEVA News Highlights
- For TEVA, its 30 day story count is now at 14.
- Over the past 26 days, the trend for TEVA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about TEVA are TEL, MG and AMPH.
Latest TEVA News From Around the Web
Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
7 Strong Buy Stocks Under $10 to Snap Up Now
Markets are missing out on these seven strong buy stocks under $10, which trade at too good a value score for savvy investors to ignore.
3 No-Brainer Stocks to Buy With $10 Right Now
As much as we'd enjoy a stock market that never declined, stocks can and do move in both directions. Last year, all three major U.S. stock indexes tumbled into respective bear markets and produced their worst returns since the financial crisis. Despite 39 official stock market corrections in the benchmark S&P 500 since the beginning of 1950, all but the current decline eventually gave way to a bull market rally that took the broader market to new highs.
15 Best Stocks Under $10 To Buy Now
In this article, we will discuss the 15 best stocks to buy now that are currently trading under $10. If you want to explore similar stocks, you can also take a look at 5 Best Stocks Under $10 To Buy Now. The stock market volatility of 2022 has carried into 2023. The year got off […]
25 Biggest Pharmaceutical Companies in the World
In this article, we will be taking a look at the 25 biggest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 biggest pharmaceutical companies in the world. There is no need to emphasize the value of the pharmaceutical industry after the Covid-19 pandemic. Without the […]
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
McKinsey Consulted VA While Advising Opioid Makers to Target Agency for Sales
Since at least 2009, McKinsey has been a consultant to the U.S. Department of Veterans Affairs. During part of that time, the consulting giant also advised some of the world’s biggest opioid producers to target the federal agency for sales of their products, according to newly released documents.
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
TEL AVIV, Israel, March 13, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India, March 09, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid®1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.
Teva to Present at the Barclays Global Healthcare Conference
TEL AVIV, Israel & PARSIPPANY, N.J., March 07, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time.
Better Generics Pharmaceutical Stock: Teva or Viatris?
Teva Pharmaceutical Industries (NYSE: TEVA) and Viatris (NASDAQ: VTRS) are two of the top makers of generic pharmaceuticals, but both healthcare companies are having to look beyond their generic and branded drugs to find a way to grow sales. While Teva's 2022 revenue was down compared to 2021, the company is forecasting revenue growth in 2023, due in part to increased sales of anti-spasm drug Austedo, as well as a likely launch of a Humira biosimilar. Viatris' revenue was also down in 2022, but its net income was up and it is expecting more than $500 million in revenue from new launches this year.